Results 21 to 30 of about 796 (164)

Long-term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program [PDF]

, 2021
Objective: We determined retention on open-label cenobamate therapy in the clinical development program to assess the long-term efficacy and tolerability of adjunctive cenobamate in individuals with uncontrolled focal seizures.
Sander, JW, Rosenfeld, WE, Steinhoff, BJ, Biton, V, Halford, JJ, Toledo, M   +5 more
core  

Therapeutic strategies during cenobamate treatment initiation: Delphi panel recommendations [PDF]

\ua9 The Author(s), 2024. The goal of epilepsy treatment is seizure freedom, typically with antiseizure medication (ASM). If patients fail to attain seizure control despite two trials of appropriately chosen ASMs at adequate doses, they are classified as
Villanueva V, Klein P, Schmitz B, Ben-Menachem E, Peltola J, Steinhoff BJ, Thomas RH   +6 more
core   +2 more sources

Intermittent fasting with medium‐chain triglycerides in drug‐resistant epilepsy: A pilot crossover trial

Epilepsia, EarlyView.
Abstract Objective Ketogenic dietary therapies can reduce seizure frequency in drug‐resistant epilepsy, but adherence to the classical ketogenic diet is often poor. Intermittent fasting supplemented with medium‐chain triglycerides (MCTs) may offer a more feasible and less restrictive alternative.
Wiebke Hahn, Emily Falk, Ayla Balzter, Tobias Foer, Shanin Maierhofer, Sophia Jaumann, Sascha Strehlau, Leona Möller, Panagiota‐Eleni Tsalouchidou, Katja Menzler, Lars Timmermann, Susanne Knake   +11 more
wiley   +1 more source

Cenobamate modulates EEG cortical activity and connectivity in individuals with drug-resistant epilepsy: a pharmaco-EEG study. [PDF]

Front Neurol
ObjectiveQuantitative electroencephalography (qEEG) metrics are demonstrated to correlate with and predict clinical response in individuals with epilepsy.
Assenza G, Sancetta B, Ricci L, Vico C, Narducci F, Boscarino M, Lanzone J, Menna P, Liguori C, Izzi F, Mercuri NB, Di Lazzaro V, Tombini M.   +12 more
europepmc   +2 more sources

Impact of cenobamate on cortical responses to transcranial magnetic stimulation in people with drug‐resistant focal epilepsy

Epilepsia Open, EarlyView.
Abstract Objective Cenobamate (CNB) is an effective antiseizure medication, though its mechanisms of efficacy remain incompletely understood. We assessed changes in cortical responses to transcranial magnetic stimulation (TMS) following CNB treatment.
Silvano R. Gefferie, Diego Jiménez‐Jiménez, Gerhard H. Visser, Robert M. Helling, Arn M. J. M. van den Maagdenberg, Josemir W. Sander, Simona Balestrini, Roland D. Thijs   +7 more
wiley   +1 more source

Hypersensitivity reaction risk when restarting cenobamate after discontinuation: Insights from a prolonged hospitalized cohort

Epilepsia Open, EarlyView.
Abstract Objective To evaluate the risk of hypersensitivity reactions, including dermatological rashes, when cenobamate (CNB) is restarted at maintenance doses after temporary discontinuation. Methods We leveraged the natural experiment of long antiseizure medication discontinuation during intracranial EEG evaluation and conducted a retrospective ...
Marina Feldman, Andreas Alexopoulos, Juan Bulacio, Dileep Nair, Vineet Punia   +4 more
wiley   +1 more source

Real‐world effectiveness of cenobamate in drug‐resistant and ultra‐refractory epilepsy: A multicenter study

Epilepsia Open, EarlyView.
Abstract Objective To evaluate the real‐world effectiveness, safety, and treatment retention of cenobamate (CNB) in patients with drug‐resistant epilepsy (DRE), including ultra‐refractory epilepsy (URE), high seizure burden, and extensive prior treatment history.
Ondřej Strýček, Jana Amlerová, Martin Pail, Jitka Kočvarová, Jana Slonková, Martin Šimčík, Kateřina Stanzelová, Monika Šibalová, Petr Marusič, Milan Brázdil   +9 more
wiley   +1 more source

Long‐term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program

, 2022
OBJECTIVE: We determined retention on open‐label cenobamate therapy in the clinical development program to assess the long‐term efficacy and tolerability of adjunctive cenobamate in individuals with uncontrolled focal seizures.
Manuel Toledo, Victor Biton, William E. Rosenfeld, Steinhoff, Bernhard, Biton, Victor, Jonathan J. Halford, Halford, Jonathan J., Sander, Josemir W., Rosenfeld, William E., Josemir W. Sander, Bernhard J. Steinhoff, Toledo, Manuel, Steinhoff, Bernhard J.   +12 more
core   +1 more source

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 1957-1976, July 2026.
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity ...
Lucy Galloway, Cinzia Dello Russo, Nicholas Bass, Elvira Bramon, Helen Cross, Natalie Curley, Sarah Curran, Helen Davies, Jana De Villiers, William Evans, Bernhard Frank, Alice Groves, Judith Hayward, Jon Higham, Dyfrig A. Hughes, Shwe Sin Kyaw, Anthony G. Marson, Ailsa McLellan, Seth Mensah, Francis O'Neill, Jane Sargison, Sanjay M. Sisodiya, Jill Swan, Joanna M. Zakrewska, Munir Pirmohamed   +24 more
wiley   +1 more source

Exploration of the mechanism of action of cenobamate

Seizure: European Journal of Epilepsy
Antiseizure medications have varied effects on neurotransmitter receptors and ion channels in the brain, yet how these mechanisms of action (MoAs) translate to clinical efficacy is not well understood. Cenobamate, a tetrazole alkyl carbamate antiseizure medication (ASM), has a dual MoA: preferential inhibition of the persistent sodium current (INaP ...
Raman, Sankar, Louis, Ferrari, Marc, Kamin   +2 more
openaire   +2 more sources